30 results about "ERYTHROCYTES AGGLUTINATION" patented technology

The invention discloses a heavy chain and light chain variable region for resisting to a canine parvovirus antibody and a gene engineering antibody, and belongs to the technical field of antibody engineering. An amino acid sequence and a nucleotide sequence of the heavy chain and light chain variable region for resisting to the canine parvovirus antibody provide supports for construction of the high-affinity and low-immunity canine parvovirus antibody. A variable region sequence of a monoclonal antibody for canine parvovirus and a murine constant region are further assembled, so that the geneengineering antibody for resisting to canine parvovirus is obtained, good activity for neutralizing CPV viruses is shown, and the gene engineering antibody has a restraining effect on erythrocyte agglutination of canine parvovirus, can be applied to research of a canine source of the monoclonal antibody for canine parvovirus and other fields, and has important meaning for pushing of development ofcanine source monoclonal antibody medicine.

A cell analyzer, an erythrocyte agglutination warning method and an erythrocyte agglutination warning system of the cell analyzer. The erythrocyte agglutination warning method includes following steps: (1) measuring volume information of cells in a sample; (2) recognizing the cells of which the volume information is larger than a preset volume threshold value to obtain an agglutinated erythrocyte group; (3) counting the number of the cells in the agglutinated erythrocyte group to obtain an agglutinated erythrocyte amount; (4) determining whether the agglutinated erythrocyte amount is large than a preset number threshold value, and if the agglutinated erythrocyte amount is large than the preset number threshold value, carrying out erythrocyte agglutination warning. Determination on the content of certain components in the cells is unnecessary since the agglutinated erythrocyte is recognized directly according to the volume of the cells, so that compared with a conventional erythrocyte agglutination warning method, the method can improve a warning accuracy and is simple, convenient and quick.

The invention provides an avian influenza H9N2 subtype virus strain with the preservation number of CGMCC No.6757. The avian influenza H9N2 subtype virus strain provided by the invention has favorable specificity and immunogenicity, the erythrocyte agglutination effect of allantoic fluid can not be inhibited by anti-NDV (Newcastle Disease Virus) positive serum, anti-EDS76 positive serum, anti-M41 positive serum, anti-H5 subtype avian influenza virus positive serum and anti-H7 subtype avian influenza virus positive serum, but can be inhibited by H9 subtype avian influenza virus positive serum, and immunized chicken can generate an HI (Hemagglutination Inbition) antibody which is specific for H9. The avian influenza H9N2 subtype virus strain provided by the invention can be used as a vaccine strain for preventing H9 subtype avian influenza of birds, and can be used for authenticating avian influenza viruses and researching epidemiology so as to have favorable market application prospects.

The invention discloses a recombinant galactose agglutinin-1 two-string protein and a preparation method thereof. The method specifically comprises the following steps of: providing a recombinant Galectin-1 protein with bioactivity through a biotechnological method; respectively transfecting BL21 to construct engineering bacteria through constructing prokaryotic expression vectors pET-22b(+)-Gal-1 and pET-22b(+)-Gal-1 (2); and then obtaining the recombinant Galectin-1 monomer protein or a recombinant Galectin-1 two-string protein through IPTG (Isopropyl Beta-D-1-Thiogalactopyranoside) induction expression and the chromatographic separation and passivation after dividing the bacteria. Through an erythrocyte agglutination test, it is proved that both the two recombinant Galectin-1 proteins have obvious bioactivity, and the bioactivity of the Galectin-1 two-string protein is higher than that of the Galectin-1 monomer protein.

The invention provides a novel determining method of the content of antigen virus of an inactivated vaccine of a recombinant bird flu H5N1 cellgen. The method comprises the following steps of: (1) preparation of MDCK (madin darby canine kidney), wherein 1.5ml of MDCK frozen cell with density of 2.0*10<6> is extracted and put in a water bath at a temperature of 37 DEG C, 10 to 15ml of cell culturefluid is added to culture for 72 hours, the cell is digested with 0.25 percent EDTA (ethylene diamine tetraacetic acid)-pancreatin, the cell nutrient fluid is diluted into MDCK cell suspension of 4.0*10<5>, the MDCK cell suspension is spread to a 96-mesh cell plate in a cell density of 40,000 per pore (0.1ml per pore), the cell plate is put in a CO2 culture case at a temperature of 37 DEG C and humidity of 5 percent to culture for 24 hours to form a compact monolayer for later use; and (2) inoculation of a recombinant bird flu H5N1 antigen, wherein recombinant bird flu H5N1 cellgen antigens in different batches are extracted and respectively added into the compact monolayer with 100mu l in each pore, and 100mu l of cell maintenance fluid is added to culture for four days, and a TCID50 (50% tissue culture infection dose) value is calculated by the number of cytopathic pores in a Reed-Muench method. The method is applicable to a cellgen vaccine for detecting the virus content by an erythrocyte agglutination test, which means that different viruses use corresponding sensitive cells.

The invention belongs to the technical field of microbiological detection, and discloses an influenza hemagglutination inhibition test detection method which comprises the following steps: pretreatingstandard reference antiserum to remove non-specific inhibin and non-specific lectin in the serum; preparing an erythrocyte suspension; determining the hemagglutination titer of the influenza virus strain; preparing four hemagglutination unit antigens for an erythrocyte agglutination inhibition test; rechecking and titrating four hemagglutination unit antigens; and performing influenza virus identification and antigen analysis by using an HAI method to obtain the serum titer of the detected serum. According to the detection method, chicken erythrocyte, turkey erythrocyte and guinea pig erythrocyte are used as raw materials to prepare erythrocyte suspension, animal erythrocyte is used for replacing human erythrocyte, and the difficulty that an experiment cannot be conducted due to lack of erythrocyte is solved.

The invention relates to a non-erythrocyte agglutination anti-PD-L1/CD47 bispecific antibody and application thereof in anti-tumour treatment. Specifically, the invention provides an anti-PD-L1/CD47 bispecific antibody or an antigen binding fragment thereof; the anti-PD-L1/CD47 bispecific antibody can be specifically bound with PD-L1 and CD47 molecules; binding of PD-L1 and PD-1 and binding of CD47 and SIRP alpha can be blocked at the same time after binding; T cells and macrophages are further activated to achieve the biological effects of resisting tumours and the like; and meanwhile, the antibody does not cause erythrocyte agglutination.

The invention relates to a colloidal gold detection card for quickly detecting rabbit hemorrhagic disease virus (RHDV) and a preparation method thereof. The method comprises the following steps: 1) preparation of paired monoclonal antibodies against RHDV, wherein the preparation processes comprise immune procedure, cell fusion, hybridoma screening and cloning and antibody preparation and purification; and 2) preparation of the colloidal gold detection card for quickly detecting rabbit hemorrhagic disease virus (RHDV), wherein the preparation processes comprise preparation of a colloidal gold monoclonal antibody, sample pad treatment, membrane spraying, determination of C and T lines, treatment of tested samples and performance determination. The method can quickly, sensitively and accurately detect RHDV infection in the liver and kidney of a rabbit, and overcomes the problem that erythrocyte agglutination test is the main method to detect the RHDV in China, thereby greatly reducing detection time and providing convenience for on-site detection.

The invention discloses a chicken embryo virus liquid virus titer measurement method. The method includes the following steps of chicken embryo inoculation position determination, sample dilution, inoculation, hole sealing, chicken embryo post-incubation, cold egg acquisition of chicken embryos, chicken embryo erythrocyte agglutination titer measurement and EID50 calculation. By the adoption of the method, the chicken embryo inoculation position is changed, the amount of virus liquid injected in an allantoic cavity is more accurate, measurement result errors are reduced, in the hole sealing process, quick-setting glue is used for replacing wax adopted for hole sealing traditionally, the hole sealing speed is high, hole sealing operation is safe, in the cold egg acquisition process, a method of gradual transition of different temperatures is selected, the situation that yolks are broken due to chicken embryo struggles caused by the large temperature difference is avoided, and therefore the accuracy of a virus titer measurement result is improved.

The invention discloses a novel coronavirus COVID-2019 detection card and a preparation method thereof. The novel coronavirus COVID-2019 detection card comprises a card supporting layer attached to detection test paper, a sample unit positioned on the card supporting layer, a preprocessing unit positioned on the card supporting layer, a marker unit positioned on the card supporting layer, a detection unit positioned on the card supporting layer, and a recycling unit positioned on the card supporting layer; the sample units correspond to the sample holes; the pretreatment unit corresponds to the pretreatment hole; a hollow or transparent sealed detection window is arranged at the position, corresponding to the detection unit, of the shell; the erythrocyte agglutination layer is provided with erythrocyte agglutinin; the endogenous interfering substance treatment layer is provided with an endogenous interfering substance conjugate; the exogenous interfering substance treatment layer is provided with an exogenous interfering substance chelating agent; a non-specific IgM antibody treatment layer is provided with an IgM chelating agent; a non-specific IgG antibody treatment layer has anIgG precipitant. The problem that interfering substances influence the detection result of the novel coronavirus is solved, and the detection accuracy is improved.

The invention relates to active polypeptide and a gene thereof, and application of the active polypeptide to pharmacy. Microhyla pulchra antioxidation peptide is cyclopeptide consisting of 12 pieces of amino acid, wherein the molecular weight is 1334.91 daltons; the isoelectric point is 8.002; the amino acid sequence is SEQ ID NO.1; and the third-position cysteine and the eleventh-position cysteine of the polypeptide form intramolecular disulfide bonds. The gene sequence of the microhyla pulchra antioxidation peptide consists of SEQ ID NO.4, and the gene encoded with the functional mature microhyla pulchra antioxidation peptide is the 187th to the 222nd position nucleotide. The gene of the microhyla pulchra antioxidation peptide deduces the mature functional polypeptide amino acid sequence, and the synthesized microhyla pulchra antioxidation peptide has strong erythrocyte agglutination and anti-oxidation functions.

The invention belongs to the technical field of veterinary drugs, and particularly relates to a Newcastle disease attenuated sugar vitrified vaccine and a preparation method thereof. The preparation raw materials of the vaccine include hatching eggs, reagents and seed virus. The reagents comprise any one or more of PBS (phosphate buffer solution) or normal saline and any one or more of a penicillin solution or a streptomycin solution; and the seed virus comprises any one or more of an HB1 strain, an F strain, a LaSota strain, a LaSota-Clone30 strain or an N79 strain, and propiolactone. The vaccine also comprises a raw material reactant for preparing the vitrified vaccine, and the reactant is specifically one or more of trehalose or agarose. According to the present invention, an erythrocyte experiment is directly performed on the generated vaccine, and the optimal attenuated virus can be found according to the optimal erythrocyte agglutination point so as to effectively ensure the performance of the vaccine.